Breaking News

Neuland Labs to Add Commercial Peptide Capacity with New India Facility in 2026

The new facility will enable client execution from small‑scale to multi‑ton commercial volumes.

Author Image

By: Charlie Sternberg

Associate Editor

Neuland Laboratories Ltd. plans to open a commercial‑scale peptide manufacturing facility in summer 2026 at its 17‑acre Bonthapally campus in Hyderabad, expanding its capacity amid rising global demand for complex peptides, including GLP‑1 drugs. The first of four planned manufacturing modules is slated to come online this summer. Neuland said that module has secured firm commitments of approximately $30 million, which will add 6,370 liters of solid‑ and liquid‑phase peptide synthesis capacit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters